Home > Boards > US Listed > Biotechs > Intercept Pharmaceuticals (ICPT)

BioVie's Coverage initiated by Tailwinds Research Group

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Trend-Setter Member Profile
 
Followed By 7
Posts 900
Boards Moderated 0
Alias Born 07/19/13
160x600 placeholder
Intercept Pharmaceuticals Announces Convertible Notes Repurchase GlobeNewswire Inc. - 9/13/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 7:02:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 7:01:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 7:01:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/1/2021 7:01:41 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 9/1/2021 8:52:12 AM
Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference GlobeNewswire Inc. - 9/1/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/23/2021 4:32:42 PM
Endo International, HEXO, Catabasis Pharmaceuticals among major healthcare premarket losers' pack Seeking Alpha - 8/20/2021 8:18:32 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/16/2021 7:01:43 PM
Tender Offer Statement by Issuer (sc To-i) Edgar (US Regulatory) - 8/16/2021 4:16:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/13/2021 7:02:00 PM
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase GlobeNewswire Inc. - 8/10/2021 9:43:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/2/2021 7:01:33 PM
Intercept Pharmaceuticals posts Q2 earnings beat on Ocaliva Strength, shares rise Seeking Alpha - 7/29/2021 8:04:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/29/2021 7:17:09 AM
Intercept Pharma EPS beats by $0.89, beats on revenue Seeking Alpha - 7/29/2021 7:06:39 AM
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 7/29/2021 7:00:00 AM
Written Communication Relating to an Issuer or Third Party (sc To-c) Edgar (US Regulatory) - 7/19/2021 5:01:30 PM
Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021 GlobeNewswire Inc. - 7/19/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 7:02:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 7:01:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 7:01:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2021 7:02:11 PM
Written Communication Relating to an Issuer or Third Party (sc To-c) Edgar (US Regulatory) - 7/1/2021 4:31:35 PM
Trend-Setter   Monday, 04/08/19 12:44:28 PM
Re: Trend-Setter post# 558
Post # of 605 
BioVie's Coverage initiated by Tailwinds Research Group
from the article:
"In my opinion, BioVie has a relatively easy path to FDA approval. Their drug, terlipressin, has been proven effective in over 40 countries. It is commonly prescribed and has a known effect on patients with liver cirrhosis. In addition, their proprietary (in the US) delivery technology has been shown to increase effectiveness while lowering toxicity in trials".

"In the near term, BioVie has results coming from their Phase 2a safety trial. These are expected early in April. The results of this will hopefully be positive, leading to a Phase 2b trial starting in the summer. Optimistically, the FDA could move BIV201 straight into a Phase 3 trial. We will learn if this is going to happen in May, but the odds of this are not very high".

"After the Company gets their results from the Phase 2a trial, I expect them to raise the funds necessary to take them through Phase 3 and onto the market. The company requires somewhere between $10 and $15 million to accomplish this. With a positive Phase 2a trial, fundraising ultimately shouldn’t be a big issue".

"Once approved, I anticipate BioVie being acquired by a larger company with a sales force, etc. The potential price for this acquisition could be over $1B. With a phase 3 trial taking about a year until completion and FDA approval, I believe an acquisition would be a 2nd half of 2020 event at the earliest. Certainly the majority owner, Terren Peizer, is looking for a large exit and not making this investment for a small win".

"With a current market cap of $30M, BioVie is an attractive investment. They have the rights to a known drug that has been proven effective over many years. They have a novel delivery technology that increases effectiveness while reducing negative side effects. Finally, they have US patents in place and orphan drug designation that will enable them to capture a large market that is currently unaddressed. I am long BioVie and look forward to holding my shares through FDA approval and an eventual liquidity event."

"I believe the end game here is an exit through a sale of the Company. In my opinion, the most likely acquirer would be Mallinckrodt as they are active in terlipressin already. Once the drug is approved, any sale of the Company would likely return well over 5x on an investors’ money with the chance of much larger gains; typically, acquisitions of drug companies with high margins like BioVie should see can range from 10 times revenue to as high as 20 times"

For full coverage check:
.https://tailwindsresearch.com/2019/04/biovie-an-undiscovered-gem/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences